International Summit on Psychedelic Therapies for Mental Illness, Melbourne, Australia
November 17, 2021 - November 20, 2021
Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2021 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy makers, business, industry, investors, consumers and other interested stakeholders.
The event will also feature a two-day pre-Summit introductory workshop program (17-18 November) for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the treatment of mental illness.
The Introductory Workshop for Psychedelic Therapies will be facilitated by leading Psychotherapist and Founder of the UK TRIPP Network Maria Papaspyrou (UK) and Clinical Psychologist for the psilocybin trials at Imperial College, Renee Harvey (UK).
The two-day Introductory Workshop for Psychedelic Therapies is open to anyone with an interest in the topic and who is considering further development of their current therapeutic skills. It is particularly for those who are aiming to work in this field as and when these therapies become legally available in Australia. It will cover an introductory background history to psychedelic medicines, how they work and how they are applied in research and clinical settings. There will be a significant practical component focussing on integration of experiences – how to understand and use the kinds of experience commonly encountered when using these substances for better self-understanding and how trained therapists might help someone apply them in their own lives. While not providing a qualification of any kind, attendees can obtain non-accredited Continuing Professional Development (CPD) certificates (related to your professional registration) for attending. The workshop will also provide a taster for the contents of the longer Professional Development Program for clinicians and trained therapists due to commence early in 2021. Please note that the introductory workshop is not a prerequisite for anyone wishing to go on to apply for the full course, and also unfortunately cannot guarantee acceptance. The longer training will include teaching by internationally recognised leaders in the field and will follow the highest standards for recognised medicine-assisted psychotherapy training.
The Summit will feature a rich program with a mixture of international and national keynotes, workshops, hot spots, panel conversations and gala dinner with Q & A.
We already have a range of leading international speakers committed for the 2-day summit including Professor David Nutt (UK) Head of Neuropsychopharmacology at Imperial College London and lead advisor on the current Compass Pathways Phase 3 Trials on psilocybin assisted therapy for treatment resistant depression, Dr Ben Sessa (UK) psychiatrist, researcher and writer and currently leading the Imperial College trials on using MDMA therapy for alcohol dependence, Dr Robin Carhart-Harris (UK) Head of the Centre for Psychedelic Research, Imperial College London, Dan Ariely (USA and Israel) James B. Duke Professor of Psychology and Behavioural Economics at Duke University, Wade Davis (Canada) Anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society and Associate Professor Matthew Johnson (USA) Associate Professor of Psychiatry at Johns Hopkins University School of Medicine with a focus on psychedelic research for the treatment of mental illness, Dr Adele Lafrance (USA / Canada) Clinical Psychologist and Research Scientist, Dr Kate Pate (USA) Neurophysiologist and writer, Dr Reid Robinson (USA) Psychedelic Psychiatrist and writer, Adam Gazzaley M.D, PHD (USA) Founder & Executive Director – Neuroscape, Vince Polito (AUS) Senior Research Fellow, Dr Lisa Reynolds (NZ) Health Psychologist and Director of the University of Auckland’s Health Psychology Practitioner Programme, Shlomi Raz (USA) Chairman and CEO of Eleusis, John Skerritt (AUS) Deputy Secretary, Health Products Regulation Group- TGA, Dr Simon Longstaff (AUS) Executive Director of The Ethics Centre, Maria Papaspyrou (UK) and Renee Harvey (UK).
Key themes will include:
- Ethical, legal, and implementation frameworks for psychedelic treatments
- The current state of mental health in Australia and existing treatments
- Clinical outcomes of psychedelic treatment for mental illness
- Therapeutic mechanisms of psychedelic treatments
- Enhancing effectiveness and minimising risks for psychedelic treatment
- The way forwards for Australia: Challenges and preparation towards creating a new paradigm
Psychedelic therapies have been granted Breakthrough Therapy status by the FDA in the USA due to current promising research in the treatment of depression and PTSD. We look forward to collaborating with you to explore psychedelic treatment options to help address the mental health crisis we currently face, and offer treatments to those who need it most.
We are delighted to extend an invitation to you and your colleagues to gather in Melbourne in November 2021.
Together we can change the paradigm for mental health.
Venues: Sofitel Melbourne On Collins, University location for Therapist 2-day workshop
Disclaimer Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.